Serplulimab is the world's first anti-PD-1 monoclonal antibody (mAb) approved for first-line treatment of ES-SCLC Serplulimab is the first and only anti-PD-1 mAb approved in the European Union (EU) ...

Small-cell lung cancer: ESMO Clinical Practice Guidelines ... is the first anti-PD-1 mAb for the first-line treatment of SCLC and has been approved in China, the EU and several SEA countries.

Scientists believe that air pollution could be a major cause behind the rise in global lung cancer cases in people that have ...

Tagrisso was linked to higher cardiac risks in patients with EGFR-mutant NSCLC, including a four-fold rise in cardiac events ...

THE proportion of people diagnosed with lung cancer who’ve never smoked is increasing, the World Health Organization (WHO) ...

MAIA Biotechnology Announces Positive Efficacy Updates for Phase 2 THIO-101 Trial in Advanced Non-Small Cell Lung Cancer ...

Estimated geographical and temporal distribution of lung-cancer incidence varied across the four main subtypes worldwide. Our ...

Hong Kong-listed Shanghai Henlius Biotech Inc, a subsidiary of Fosun Pharma, announced on Wednesday that its anti-PD-1 mAb, ...

Susan Williams,seated center, a patient at the John B. Amos Cancer Center in Columbus, Georgia, is receiving a new cancer treatment known as Bispecific T-Cell Engager (BiTE) therapies on Feb. 11, 2025 ...

A treatment for patients living with advanced non-small cell lung cancer (NSCLC) who failed two or more standard-of-care (SOC) options could extend overall survival (OS) to 16.9 months according to ...

Many people with lung cancer develop anemia, especially after chemotherapy treatment. Anemia occurs when your red blood cell levels drop too low. In one 2021 study, about 32% of the people with ...